Albireo Price to Earning from 2010 to 2023

Summary

ALBODelisted Stock

USD 44.15 0.75 1.67%

Albireo Pharma Weighted Average Shares is very stable at the moment as compared to the past year. Albireo Pharma reported last year Weighted Average Shares of 22.1 Million. As of 22nd of March 2023, Weighted Average Shares Diluted is likely to grow to about 23.8 M, while Consolidated Income is likely to drop (33 M).

Check Albireo Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Albireo main balance sheet or income statement drivers, such as Direct Expenses of 1.2 M, Cost of Revenue of 1.2 M or Gross Profit of 48.7 M, as well as many exotic indicators such as Long Term Debt to Equity of 0.0502, PPandE Turnover of 67.56 or Receivables Turnover of 6.79. Albireo financial statements analysis is a perfect complement when working with Albireo Pharma Valuation or Volatility modules. It can also supplement various Albireo Pharma Technical models . Please continue to Trending Equities.

Albireo Price to Earning Breakdown

Showing smoothed Price to Earnings Ratio of Albireo Pharma with missing and latest data points interpolated. An alternative to [PE] representing the ratio between [Price] and [EPSUSD].Albireo Pharma's Price to Earnings Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Albireo Pharma's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (4.16) X

10 Years Trend

Compare to Others All Fundamentals

Price to Earnings Ratio

Timeline

Albireo Price to Earning Regression Statistics

	Arithmetic Mean	(5.18)
	Geometric Mean	3.14
	Coefficient Of Variation	(87.59)
	Mean Deviation	3.72
	Median	(2.54)
	Standard Deviation	4.54
	Sample Variance	20.59
	Range	12.75
	R-Value	(0.84)
	Mean Square Error	6.51
	R-Squared	0.71
	Significance	0.00016123
	Slope	(0.91)
	Total Sum of Squares	267.67

Albireo Price to Earning History

	2023	-12.15
	2022	-11.84
	2021	-13.16
	2020	-5.57
	2019	-5.04
	2018	-6.23
	2017	-8.2
	2016	-1.34
	2014	-0.4
	2013	-2.53
	2012	-2.54

About Albireo Pharma Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Albireo Pharma income statement, its balance sheet, and the statement of cash flows. Albireo Pharma investors use historical funamental indicators, such as Albireo Pharma's Price to Earning, to determine how well the company is positioned to perform in the future. Although Albireo Pharma investors may use each financial statement separately, they are all related. The changes in Albireo Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Albireo Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Albireo Pharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Albireo Pharma. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for 2023
Price to Earnings Ratio	(11.84)	(12.15)
Earnings Before Interest Taxes and Depreciation Amortization EBITDA	-17.8 M	-19.3 M
Earnings before Tax	-30.6 M	-33 M

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Albireo Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Albireo Pharma's short interest history, or implied volatility extrapolated from Albireo Pharma options trading.

Pair Trading with Albireo Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Albireo Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Albireo Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Albireo Pharma

-	0.87	ABIO	ARCA Biopharma	Fiscal Quarter End 31st of March 2023	Pair Corr
-	0.71	ACER	Acer Therapeutics	Financial Report 15th of May 2023	Pair Corr
-	0.59	AADI	Aadi Bioscience	Earnings Call This Week	Pair Corr
-	0.54	ACGN	Aceragen	Earnings Call This Week	Pair Corr

The ability to find closely correlated positions to Albireo Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Albireo Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Albireo Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Albireo Pharma to buy it.

The correlation of Albireo Pharma is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Albireo Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Albireo Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Albireo Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Please continue to Trending Equities. Note that the Albireo Pharma information on this page should be used as a complementary analysis to other Albireo Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Other Consideration for investing in Albireo Stock

If you are still planning to invest in Albireo Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Albireo Pharma's history and understand the potential risks before investing.

	Global Correlations Find global opportunities by holding instruments from different markets
	Portfolio Anywhere Track or share privately all of your investments from the convenience of any device
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Analyst Recommendations Analyst recommendations and target price estimates broken down by several categories

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2023 Macroaxis LLC